Abstract
Background: Diseases perceived as neglected tropical infections are generally caused by parasites which reach poor, underserved populations (primarily infrastructure), cause serious damage to health, and many deaths. AIDS and tuberculosis, (although not classified as neglected by WHO), are discriminated against infections which cause great social damage. The drugs currently used to treat these diseases do not have the desired effectiveness, enable the emergence of resistant strains, and in most cases are difficult to obtain. Few pharmaceutical companies are investing in new drug research for neglected diseases, for lack of financial return. This review reports the major neglected diseases, AIDS, tuberculosis, their targets, and research on multi-target drugs. Methods: The studies for new drugs against these infections involve in silico methods, synthesis, structural determinations, analytical analysis and other experimental assays. Results: A new single compound, forecasting possible pharmacodynamic and pharmacokinetic interactions becomes a simpler process; it is also believed that these drugs are safer and more efficient, since they act with synergism on different targets. It occurs but the emergence of new resistant strains and side effects. Conclusion: Multi-target drugs represent a new alternative to find new lead compounds. A ligand that targets two or more receivers may be seen as a potential drug, combating infection by different routes.
Keywords: Chagas disease, African trypanosomosis Human, leishmaniasis, dengue, malaria, AIDS, tuberculosis, multitarget drugs.
Current Pharmaceutical Design
Title:Multi-Target Drugs for Neglected Diseases
Volume: 22 Issue: 21
Author(s): Luciana Scotti, Francisco J.B.M. Filho, Ricardo O. de Moura, Frederico F. Ribeiro, Hamilton Ishiki, Marcelo S. da Silva, José M.B. Filho and Marcus T. Scotti
Affiliation:
Keywords: Chagas disease, African trypanosomosis Human, leishmaniasis, dengue, malaria, AIDS, tuberculosis, multitarget drugs.
Abstract: Background: Diseases perceived as neglected tropical infections are generally caused by parasites which reach poor, underserved populations (primarily infrastructure), cause serious damage to health, and many deaths. AIDS and tuberculosis, (although not classified as neglected by WHO), are discriminated against infections which cause great social damage. The drugs currently used to treat these diseases do not have the desired effectiveness, enable the emergence of resistant strains, and in most cases are difficult to obtain. Few pharmaceutical companies are investing in new drug research for neglected diseases, for lack of financial return. This review reports the major neglected diseases, AIDS, tuberculosis, their targets, and research on multi-target drugs. Methods: The studies for new drugs against these infections involve in silico methods, synthesis, structural determinations, analytical analysis and other experimental assays. Results: A new single compound, forecasting possible pharmacodynamic and pharmacokinetic interactions becomes a simpler process; it is also believed that these drugs are safer and more efficient, since they act with synergism on different targets. It occurs but the emergence of new resistant strains and side effects. Conclusion: Multi-target drugs represent a new alternative to find new lead compounds. A ligand that targets two or more receivers may be seen as a potential drug, combating infection by different routes.
Export Options
About this article
Cite this article as:
Scotti Luciana, J.B.M. Filho Francisco, O. de Moura Ricardo, F. Ribeiro Frederico, Ishiki Hamilton, S. da Silva Marcelo, M.B. Filho José and T. Scotti Marcus, Multi-Target Drugs for Neglected Diseases, Current Pharmaceutical Design 2016; 22 (21) . https://dx.doi.org/10.2174/1381612822666160224142552
DOI https://dx.doi.org/10.2174/1381612822666160224142552 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Advances in the Diagnosis and Therapy of Primary Adrenal Insufficiency
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Immunomodulation Mechanism of Antidepressants: Interactions between Serotonin/Norepinephrine Balance and Th1/Th2 Balance
Current Neuropharmacology Editorial
Infectious Disorders - Drug Targets A Review of Antimycobacterial Drugs in Development
Mini-Reviews in Medicinal Chemistry Novel Drug-Induced Pulmonary Complications in Cancer Patients You Can Save Life!
Current Respiratory Medicine Reviews Structure-and-Mechanism-Based Design and Discovery of Type II Mycobacterium Tuberculosis Dehydroquinate Dehydratase Inhibitors
Current Topics in Medicinal Chemistry DNA Vaccines.
Current Molecular Medicine Orchestration of Host-Pathogen Interaction: Relevance of Iron in Generation of Potent Anti-M. tuberculosis Immunity
Current Pharmaceutical Biotechnology IBD Modern Concepts, Nano Drug Delivery and Patents: An Update
Recent Patents on Nanomedicine Transcriptional Responses of Mycobacterium tuberculosis Exposed to Adverse Conditions In Vitro
Current Molecular Medicine Phosphine-Gold(I) Compounds as Anticancer Agents: General Description and Mechanisms of Action
Anti-Cancer Agents in Medicinal Chemistry Target Validation: Linking Target and Chemical Properties to Desired Product Profile
Current Topics in Medicinal Chemistry Nine Medico-Legal Pitfalls in Inflammatory Bowel Disease in the United States
Current Drug Targets Decaprenylphosphoryl-β-D-Ribose 2-Epimerase from Mycobacterium tuberculosis is a Magic Drug Target
Current Medicinal Chemistry Nucleotide Second Messenger Signaling as a Target for the Control of Bacterial Biofilm Formation
Current Topics in Medicinal Chemistry Therapeutic Applications of Nanoemulsion Based Drug Delivery Systems: A Review of Patents in Last Two Decades
Recent Patents on Drug Delivery & Formulation Liposomes: Targeted and Controlled Delivery System
Drug Delivery Letters Design and Development of ChemInfoCloud: An Integrated Cloud Enabled Platform for Virtual Screening
Combinatorial Chemistry & High Throughput Screening Bioactive Peptides from Marine Sources as Potential Anti-Inflammatory Therapeutics
Current Protein & Peptide Science A Facile Synthesis and Anticancer Activity Evaluation of Spiro Analogues of Benzothiazolylchromeno/pyrano Derivatives
Letters in Drug Design & Discovery